×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Gritstone lays off 40% of team after delayed launch of COVID vax trial
Fierce Biotech
Gritstone is laying off 40% of staff after delaying the start of a phase 2 trial for a COVID vaccine, which pushed back the receipt of...
3 months ago
Gritstone Bio says personalized cancer vaccine falls short in key trial
STAT
The company said it plans to launch a Phase 3 study in 2025, but that will likely be dependent on having adequate funds.
2 months ago
Gritstone's BARDA-funded COVID vaccine faces manufacturing-related trial delay
Fierce Pharma
After Gritstone bio nabbed $433 million in federal funds to test its next-generation COVID-19 vaccine candidate, the planned phase 2b trial...
3 months ago
Gritstone Bio Eyes Pivotal Trial for Personalized Cancer Vaccine as Early ctDNA Endpoint Disappoints
Precision Medicine Online
NEW YORK – Gritstone Bio is gearing up for talks with regulators about moving its personalized neoantigen cancer vaccine, Granite,...
2 months ago
Gritstone Oncology Announces Board of Directors Changes - TipRanks.com
Tipranks
An update from Gritstone Oncology Inc (GRTS) is now available. Steve Krognes has decided not to seek re-election to Gritstone bio, Inc.'s Board of Directors...
1 month ago
Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering
BioSpace
The biotech's personalized neoantigen vaccine for colorectal cancer did not demonstrate a molecular response difference from the control arm...
2 months ago
GRTS Stock Quote Price and Forecast
CNN
View Gritstone bio, Inc. GRTS stock quote prices, financial information, real-time forecasts, and company news from CNN.
3 months ago
What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?
Yahoo Finance
Tuesday, Gritstone Bio Inc (NASDAQ:GRTS) released preliminary data from the ongoing, signal-seeking Phase 2 portion of the Phase 2/3 study...
2 months ago
Gritstone ground down by phase 2 cancer vaccine fail, sparking race against cash to gather more data
Fierce Biotech
Gritstone bio's gamble on a novel endpoint has backfired. The cancer vaccine failed to trigger hoped-for changes in circulating tumor DNA...
2 months ago
Earnings call: Gritstone bio details progress in cancer vaccine trials By Investing.com
Investing.com
Gritstone bio (GRTS) has unveiled promising preliminary data from its GRANITE personalized cancer vaccine program during its First Quarter...
3 weeks ago